|Year : 2017 | Volume
| Issue : 2 | Page : 77-80
Distant skeletal muscle metastasis to sternocleidomastoid in the setting of recurrent papillary thyroid carcinoma
Nitish Virmani, Jyoti Dabholkar
Department of Otorhinolaryngology and Head-Neck Surgery, Seth G.S. Medical College and KEM Hospital, Mumbai, Maharashtra, India
|Date of Web Publication||26-May-2017|
H. No. 576, Sector 37, Faridabad - 121 003, Haryana
Source of Support: None, Conflict of Interest: None
Papillary thyroid carcinoma (PTC), the most common form of differentiated thyroid cancer, is characterized by an indolent course and excellent prognosis. Although its spread to regional lymph nodes is well known, distant metastases are seen only in a minority of patients with lungs being the most common site. Skeletal muscle metastases are extremely rare even in follicular thyroid carcinoma, in which hematogenous spread is known to occur. We describe a case of skeletal muscle metastasis to sternocleidomastoid muscle in a case of PTC in the setting of local recurrence.
Keywords: Metastasis, papillary thyroid carcinoma, positron emission tomography scan, skeletal muscle
|How to cite this article:|
Virmani N, Dabholkar J. Distant skeletal muscle metastasis to sternocleidomastoid in the setting of recurrent papillary thyroid carcinoma. Thyroid Res Pract 2017;14:77-80
|How to cite this URL:|
Virmani N, Dabholkar J. Distant skeletal muscle metastasis to sternocleidomastoid in the setting of recurrent papillary thyroid carcinoma. Thyroid Res Pract [serial online] 2017 [cited 2020 Jul 9];14:77-80. Available from: http://www.thetrp.net/text.asp?2017/14/2/77/207134
| Introduction|| |
Differentiated thyroid cancers (DTCs) are generally characterized by an indolent progression and a 10-year survival rate as high as 80%–95%. They usually remain localized to the gland. Distant metastases are seen only in a minority of patients, the most common sites being lungs followed by mediastinal lymph nodes and bone. Rarely, they have been reported to involve brain, breast, liver, kidney, and skin. Skeletal muscle metastases are extremely uncommon in DTC, and only a few cases have been reported in literature. We describe a case of recurrent papillary thyroid carcinoma (PTC) with a focal metastatic deposit within the sternocleidomastoid muscle.
| Case Report|| |
A 45-year-old woman had undergone total thyroidectomy at a peripheral center in 2010. Unfortunately, no surgical records were available for review. She had stopped taking thyroxine supplements around 2 years ago. In 2015, she presented to us with progressively increasing neck swelling for 1 year. Physical examination revealed 8 cm × 7 cm soft, cystic, nontender swelling in the anterior neck extending between anterior borders of either sternocleidomastoid muscle. Overlying skin was fixed to the underlying tumor. There was an overlying healthy scar. There was no clinical evidence of retrosternal extension. A 2 cm × 2 cm hard, nontender, and mobile swelling was palpable over the right sternocleidomastoid muscle at the level of hyoid bone [Figure 1].
|Figure 1: Clinical photograph showing the large anterior neck swelling with overlying scar from previous surgery. Arrows mark the site of swelling within the sternocleidomastoid muscle|
Click here to view
Fine needle aspiration cytology from anterior swelling was reported as malignant thyroid lesion, which could not be typed, and that from lateral swelling was suggestive of metastasis from PTC. Computed tomography (CT) scan was done to ascertain the extent of local recurrence. The lateral swelling was visualized as an intensely enhancing nodule with scattered foci of necrosis, entirely within the right sternocleidomastoid muscle, suggestive of intramuscular metastatic deposit [Figure 2]. Positron emission tomography (PET)-CT was done to ascertain distant metastasis in the setting of recurrent disease [Figure 3].
|Figure 2: Contrast-enhanced computed tomography scan. Intensely enhancing nodule seen entirely within the right sternocleidomastoid muscle with scattered foci of necrosis|
Click here to view
|Figure 3: Positron emission tomography-computed tomography fusion images. Fluorodeoxyglucose avid recurrence in the thyroid bed with maximum standardized uptake value of 11.0 ml/g. A focal lesion within the right sternocleidomastoid can be seen with maximum standardized uptake value of 9.42 ml/g. Multiple fluorodeoxyglucose avid nodules in both lung fields (maximum standardized uptake value = 8.77 ml/g)|
Click here to view
Her thyroid function tests (T3 <20 ng/dl; T4 <0.47 μg/dl; thyroid-stimulating hormone (TSH) >60 μIU/ml) were suggestive of severe hypothyroidism. We started her on 200 μg/day of oral levothyroxine for 2 days followed by 100 μg/day. Her TSH levels normalized in 2 weeks (4.17 μIU/ml). Subsequently, she underwent wide excision of local recurrence (including involved skin) and bilateral central and lateral compartment neck dissection. The intramuscular metastatic deposit was identified within the upper third of sternocleidomastoid muscle. This portion of muscle was excised [Figure 4]. Final histopathology was suggestive of PTC with metastasis to sternocleidomastoid. Five metastatic nodes were identified. She was referred for adjuvant radioiodine therapy but unfortunately was lost to follow-up thereafter.
|Figure 4: Intraoperative photograph. Metastatic nodule identified within the right sternocleidomastoid. Upper half of muscle was excised with a wide margin|
Click here to view
| Discussion|| |
The risk of distant metastases is greater in follicular thyroid carcinoma because of its tendency to spread through hematogenous route. PTC, however, typically disseminates to regional lymph nodes. Distant metastases from PTC occur with a frequency ranging from 1.73% to 8.4% in most studies. The most common site is lung followed by mediastinal lymph nodes and bone. Rarely, metastatic disease can involve liver, brain, breast, kidney, ovaries, and skin.
Hematogenous metastasis to muscle is extremely rare even though it forms >40% of total body weight. A probable hypothesis is that skeletal muscle is a hostile environment for retention and proliferation of cancer cells, including muscle motion, unadapted muscle pH, and muscle's ability to remove tumor-produced lactic acid.
It is difficult to ascertain the exact incidence of skeletal muscle metastasis in DTC; only a few isolated case reports exist in literature. Metastatic deposits have been found in erector spinae, vastus medialis, gluteus maximus, gluteus medius, biceps, and rectus abdominis muscle.,,,,, Most of these have been associated with distant metastasis to other sites although isolated muscle deposits have also been reported. There were coexistent pulmonary metastatic deposits in our case.
Iodine-131 whole-body scan is a sensitive test to evaluate DTC patients for possible metastatic disease. However, clinicians should be aware that false-negative radioactive iodine scans are seen in up to 20% of patients with original well-DTCs. The role of fluorodeoxyglucose (FDG) PET/CT in identifying disease in such patients is well known. FDG PET/CT also plays an indispensable role in evaluating patients with recurrent neck disease which was the case in our patient. In the presence of iodine-avid residual or recurrent thyroid lesion in the neck, iodine-131 whole-body scan would be unable to pick up distant metastatic disease, thereby necessitating an FDG-PET scan. Moreover, iodine scintigraphy may fail to localize the metastatic foci because of its lack of anatomic detail. PET/CT, single-photon emission CT, and magnetic resonance imaging (MRI) allow for better and accurate localization.
To the best of our knowledge, this is the first case of sternocleidomastoid metastasis reported in literature. One may expect this muscle to be involved by contiguity, either from adjacent thyroid tumor or from underlying metastatic nodes. Even clinically, a swelling palpable in this region would generally be considered a lymph node swelling. However, CT scan correctly identified this swelling to be completely intramuscular. This was further confirmed by intramuscular avid uptake of 18 FDG on PET/CT scanning. There have been reports of involvement of sternocleidomastoid muscle by needle track seeding from fine needle aspiration biopsy  and ectopic seeding, following transaxillary robotic thyroid surgery. This possibility does exist in our case too since spillage could have occurred in the first surgery, the details of which are not available with us. However, the presence of isolated cancerous deposit completely within the muscle makes distant metastasis a more likely possibility.
The presence of distant metastases is the most significant poor prognostic factor for survival, with only 50% of metastatic patients surviving after 10 years. An important factor in our patient was TSH levels. She had severe hypothyroidism with grossly elevated TSH levels. TSH being a growth factor for thyroid cells, any increase in TSH level may stimulate cancer growth.
Most of the reported cases of muscle metastasis have been treated by radical excision and radioiodine therapy.,, External beam radiotherapy has been used for unresectable muscle metastatic deposits. We excised the upper thirds of muscle containing the metastatic deposit during excision of the local recurrence as both were accessible through the same incision. Unfortunately, our patient was lost to follow-up after we referred her for radioiodine therapy.
Lung and bone, being common sites of distant metastasis, usually draw significant concern by clinicians. Rare sites, however, may be missed in the clinical setting. Recognizing patterns of these rare metastases has a significant impact on clinical decision-making and ascertaining prognosis.
| Conclusion|| |
Even though skeletal muscle metastasis is an extremely rare manifestation of PTC, one should be aware of the possibility during postthyroidectomy follow-up of patients, especially in elderly and those with aggressive primary tumors. CT, MRI, and PET allow for superior localization of intramuscular metastatic deposits. Radical surgical excision and radioiodine therapy remain the cornerstone of management.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control. Surgery 2008;143:35-42.
Lin JD, Chao TC, Chou SC, Hsueh C. Papillary thyroid carcinomas with lung metastases. Thyroid 2004;14:1091-6.
Seely S. Possible reasons for the high resistance of muscle to cancer. Med Hypotheses 1980;6:133-7.
Luo Q, Luo QY, Sheng SW, Chen LB, Yu YL, Lu HK, et al.
Localization of concomitant metastases to kidney and erector spinae from papillary thyroid carcinoma using (131) I-SPECT and CT. Thyroid 2008;18:663-4.
Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, et al.
Distant, solitary skeletal muscle metastasis in recurrent papillary thyroid carcinoma. Thyroid 2011;21:1027-31.
Chaffanjon PC, Sturm N, Caravel JP, Chabre O, Brichon PY. Pelvic muscular metastasis of well differentiated thyroid carcinoma. Ann Chir 2004;129:100-2.
Tunio MA, Alasiri M, Riaz K, Alshakwer W, Alarifi M. Skeletal muscle metastasis as an initial presentation of follicular thyroid carcinoma: A case report and a review of the literature. Case Rep Endocrinol 2013;2013:192573.
Pucci A, Suppo M, Lucchesi G, Celeste A, Viberti L, Pellerito R, et al.
Papillary thyroid carcinoma presenting as a solitary soft tissue arm metastasis in an elderly hyperthyroid patient. Case report and review of the literature. Virchows Arch 2006;448:857-61.
Zhao LX, Li L, Li FL, Zhao Z. Rectus abdominis muscle metastasis from papillary thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med 2010;35:360-1.
Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18) F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
Karwowski JK, Nowels KW, McDougall IR, Weigel RJ. Needle track seeding of papillary thyroid carcinoma from fine needle aspiration biopsy. A case report. Acta Cytol 2002;46:591-5.
Spencer-Segal JL, Malloy K, Wong KK, Giordano TJ, Jaffe CA. Thyroid Seeding after Transaxillary Thyroid Surgery. Poster session presented at: Endo 2015. 97th Annual Meeting of the Endocrine Society; 2015 Mar 5-8; San Diego, CA.
Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, et al.
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95:1516-27.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]